209
0 Kommentare
Biomerica Announces inFoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 - Seite 2
The inFoods IBS positive clinical data will be presented during the highly anticipated IBS Clinical Session at the upcoming 2024 Digestive Disease Week (DDW) in Washington D.C., the premier international gathering of healthcare professionals specializing in digestive diseases.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal
and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Lesen Sie auch
About inFoods
The inFoods IBS test is designed to assess a patient’s above normal immunoreactivity to specific foods utilizing a simple finger-stick blood sample. Instead of difficult to manage broad dietary
restrictions, physicians can now use the inFoods IBS information to make targeted, patient-specific recommendations about trigger foods that, when removed from the diet, may alleviate IBS symptoms
such as pain, bloating, diarrhea and constipation. The inFoods IBS test and clinical outcomes were studied at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center
Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for improvement in the Abdominal Pain Intensity (API) responder
endpoint of >30% reduction in pain, for IBS patients in the treatment diet arm was greater than patients in the placebo diet arm (p-value of 0.0246). The improvement for patients in the
treatment arm versus the placebo arm is considered clinically significant and for certain endpoints is similar and, in some cases, better than the current drugs in the market. Further information
about Biomerica’s patented inFoods Technology Platform can be found at: https://biomerica.com/inFoods/our-technology/.